Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy
Circulation: Heart Failure · 2024-12 · 17 (12)
DOI: 10.1161/circheartfailure.124.012135 ↗Kurz gefasst
Leserbrief in der Zeitschrift Circulation: Heart Failure, 2024-12. Verfasst von Yousuf Razvi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medicine, National Amyloidosis Centre, University College London, Royal Free Hospital, United Kingdom (Y.R., A.M.-N., A.I., L.V., R.P., J…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: BridgeBio Pharma, Inc..
Abstract (Originalsprache)
ransthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure.Acoramidis, a high-affinity TTR (transthyretin) stabilizer, inhibits tetrameric TTR dissociation, which can lead to amyloid fibrils.ATTRibute-CM (a phase 3, multicenter, double-blind trial) randomized participants with ATTR-CM to receive acoramidis or placebo (2:1).It met its primary hierarchical end point of mortality, cardiovascular-related hospitalization, change in NT-proBNP (N-terminal pro-B-type natriuretic peptide), and 6-minute walk test (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Medicine, National Amyloidosis Centre, University College London, Royal Free Hospital, United Kingdom (Y.R., A.M.-N., A.I., L.V., R.P., J.D.G., M.F.).
- Medical University of South Carolina, Charleston (D.P.J.).
- National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (P.K.).
- Richmond Pharmacology, London, United Kingdom (L.E., J.T.).
- BridgeBio Pharma Inc, San Francisco, CA (J.D., J.-F.T., A.C., S.S., L.K., J.C.F.).
ORCID-Profile: Yousuf Razvi, Daniel P Judge, Adam Ioannou, Lucia Venneri, Rishi Patel, Julian D Gillmore, Peter Kellman, Laura Edwards, Jorg Taubel, Jing Du, Adam Castaño, Suresh Siddhanti, Leonid Katz, Jonathan C Fox, Marianna Fontana
Förderung
- BridgeBio Pharma, Inc.
Zitieren
APA
Razvi, Y., Judge, D. P., Martinez-Naharro, A., Ioannou, A., Venneri, L., Patel, R., Gillmore, J. D., Kellman, P., Edwards, L., Taubel, J., Du, J., Tamby, J. F., Castaño, A., Siddhanti, S., Katz, L., Fox, J. C., & Fontana, M. (2024). Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy. Circulation: Heart Failure, 17(12). https://doi.org/10.1161/circheartfailure.124.012135
Vancouver
Razvi Y, Judge DP, Martinez-Naharro A, Ioannou A, Venneri L, Patel R, et al. Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy. Circulation: Heart Failure. 2024;17(12). doi:10.1161/circheartfailure.124.012135
BibTeX
@article{Razvi2024,
author = {Razvi, Yousuf and Judge, Daniel P and Martinez-Naharro, Ana and Ioannou, Adam and Venneri, Lucia and Patel, Rishi and Gillmore, Julian D and Kellman, Peter and Edwards, Laura and Taubel, Jorg and Du, Jing and Tamby, Jean-François and Castaño, Adam and Siddhanti, Suresh and Katz, Leonid and Fox, Jonathan C and Fontana, Marianna},
title = {Effect of Acoramidis on Myocardial Structure and Function in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Cardiac Magnetic Resonance (CMR) Substudy},
journal = {Circulation: Heart Failure},
year = {2024},
volume = {17},
number = {12},
doi = {10.1161/circheartfailure.124.012135}
}
EUVIMED